Home About us Technology Pipeline Clinical trials News Careers Contact us Home About us Technology Pipeline Clinical trials News Careers Contact us First patient now successfully dosed in the EG110A clinical study being conducted at four leading US institutions Phase 1b/2a study to recruit 16 patients with neurogenic detrusor overactivity (neurogenic bladder) -related incontinence following spinal cord injury First application worldwide of non-replicative herpes-based vectors in neuro-urology Op

Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks Treatment High Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary Medications With Patient’s Pruritus Almost Completely Eliminated, Patient Continues to Experience Zero Nightly Sleep Disturbance No Adverse Events Reported from 6 Weeks of Whole Body Treatment with QRX003 Approval Received to Initiate Whole Body Testing of a Second Pediatric Patien

iStock, yuelan Johnson & Johnson will not appeal the dismissal of its bankruptcy proposal. The U.S. Bankruptcy Court in Houston on Tuesday dismissed Johnson & Johnson ’s latest bankruptcy bid to resolve thousands of lawsuits related to its talc baby powder, according to several media reports. J&J and its subsidiary, Red River Talc, had proposed a $9 billion bankruptcy package to settle cancer claims linked to its talc product. If approved, it would have been one of the biggest mass tort settle

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs. “We are encoura

Download PDF Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer’s disease recently published in The Journal of Prevention of Alzheimer's Disease NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), presented extended results from its

During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC) Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD™ 2025 demonstrates improvements on endpoints measuring cognitive fluctuations and working memory The results d

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, April 1, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces that it has entered into a debt settlement agreement with THECCSGROUP (the " Lender") to settle an aggregate of $60,000 in debt owed to the Lender by issuing 1,200,000 common shares in the capital of the Company (each, a " Share") at a deemed value of $0.05 pe

Unlearn, an AI-enabled company creating digital twins of clinical trial participants, announced a partnership to advance ALS research with biotechnology company Trace Neuroscience, which creates genomic therapies for neurodegenerative diseases. Unlearn, founded in 2017, uses machine learning to create digital twins of clinical trial participants before being randomized in a controlled trial. The digital twin can provide researchers insight into participants' health outcomes. The company pitches

HOUSTON, April 1, 2025 /PRNewswire/ -- Spanios is pleased to announce strategic partnership with GlioGuard aimed at propelling discovery and validation of groundbreaking therapeutic options for Glioblastoma (GBM). GBM is a malignant brain cancer amongst the most lethal types of cancer affecting 3.19 per 100'000 individuals of working age with a five-year survival rate of only 6.8 percent. Following resection and pharmacological therapy, tumor relapses make the average prognosis less than 12-18 m

Liquidia, Pulmovant, and Gossamer Bio Partner with Nonprofit to Showcase Cutting-Edge Clinical Trials and Breakthrough Therapies LOS ANGELES, April 1, 2025 /PRNewswire/ -- phaware® global association is set to launch an exclusive series of special edition episodes of its acclaimed "I'm Aware That I'm Rare: the phaware® podcast," delving into the fast-evolving world of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). Kicking off on April 7th, this captivating series wi